Rabbit Acetylcholine, Conjugated Polyclonal Antibody | anti-CHRNA1 antibody

Acetylcholine, Conjugated

Cat. Num. AAA630575

• Gene Names: CHRNA1; ACHRA; ACHRD; CHRNA; CMS2A; FCCMS; SCCMS
• Applications: ELISA, Immunohistochemistry, Immunocytochemistry
• Purity: Purified; Antiserum previously preabsobed on protein carriers, and purified by ammonium sulfate precipitation and gel filtration.
• Synonyms: Acetylcholine; Conjugated; Polyclonal Antibody; Anti -Acetylcholine; anti-CHRNA1 antibody

• Host: Rabbit
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes protein conjugated Acetylcholine. See additional crossreactivity data.
• Purity/Purification: Purified; Antiserum previously preabsobed on protein carriers, and purified by ammonium sulfate precipitation and gel filtration.
• Form/Format: Supplied as a liquid in PBS, pH 7.2, before the addition of glycerol to 40%. No preservative added.

• Applicable Applications for anti-CHRNA1 antibody: ELISA (EL/EIA), Immunohistochemistry (IHC), Immunocytochemistry (ICC)
• Application Notes: Suitable for use in ELISA, Immunohistochemistry and Immunocytochemistry.; Dilution: ELISA: 1:2000-1:5000.
• Immunogen: Choline-glutaric anhydride (GA)-BSA
• Preparation and Storage: May be stored at 4 degree C for short-term only. For long-term storage, store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Product Categories/Family for anti-CHRNA1 antibody

Antibodies; Abs to Neuroscience

NCBI and Uniprot Product Information

• NCBI GI #: 87567783
• NCBI GeneID: 1134
• NCBI Accession #: NP_001034612.1
• NCBI GenBank Nucleotide #: NM_001039523.2
• UniProt Accession #: P02708; B4DRV6; D3DPE8
• Molecular Weight: 54,546 Da
• NCBI Official Full Name: acetylcholine receptor subunit alpha isoform a
• NCBI Official Synonym Full Names: cholinergic receptor, nicotinic, alpha 1 (muscle)
• NCBI Official Symbol: CHRNA1
• NCBI Official Synonym Symbols: ACHRA; ACHRD; CHRNA; CMS2A; FCCMS; SCCMS
• NCBI Protein Information: acetylcholine receptor subunit alpha; nicotinic cholinergic receptor alpha 1; muscle nicotinic acetylcholine receptor; nicotinic acetylcholine receptor alpha subunit; acetylcholine receptor, nicotinic, alpha 1 (muscle); cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)
• UniProt Protein Name: Acetylcholine receptor subunit alpha
• Protein Family: Acetylcholine receptor
• UniProt Gene Name: CHRNA1
• UniProt Synonym Gene Names: ACHRA; CHNRA
• UniProt Entry Name: ACHA_HUMAN

NCBI Description

The muscle acetylcholine receptor consiststs of 5 subunits of 4 different types: 2 alpha subunits and 1 each of the beta, gamma, and delta subunits. This gene encodes an alpha subunit that plays a role in acetlycholine binding/channel gating. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Nov 2012]

Uniprot Description

nAChRA1: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL). Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS). SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS). FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha- 1/CHRNA1 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Channel, cation; Channel, ligand-gated; Membrane protein, multi-pass; Receptor, misc.; Membrane protein, integral

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: nicotinic acetylcholine-gated receptor-channel complex; postsynaptic membrane; cell surface; plasma membrane; cell junction; neuromuscular junction

Molecular Function: acetylcholine receptor activity; ion channel activity; acetylcholine binding; nicotinic acetylcholine-activated cation-selective channel activity

Biological Process: skeletal muscle contraction; muscle maintenance; synaptic transmission; regulation of membrane potential; transport; neuromuscular process; generation of action potential; neuromuscular synaptic transmission; skeletal muscle growth; signal transduction; musculoskeletal movement; neuromuscular junction development

Disease: Myasthenic Syndrome, Congenital, Fast-channel; Myasthenic Syndrome, Congenital, Slow-channel; Multiple Pterygium Syndrome, Lethal Type